Dr. Yossi Gilgun-Sherki, an independent Clinical & Scientific Advisor, has more than 20 years of experience in academic research & the pharmaceutical industry, leading a broad spectrum of drug development activities & biotech projects overseeing in all stages and in various companies.
In his current position, Dr. Gilgun-Sherki provides clinical, scientific, medical and overall R&D consultation on drug/medical device development, with specific focus on pre-clinical and clinical studies design, to biotech firms and pharma companies.
In his previous role Dr. Gilgun-Sherki served as Head of Specialty Products at Dexcel Pharma, where he was leading the R&D activities of all innovative products within the specialty portfolio, and prior to that he has served as Global Clinical Program Leader & Senior Clinical Scientist at Teva Global Innovative R&D group, where he was responsible for all clinical development activities and new products evaluations within the CNS Clinical Development & Medical Section.
Before joining Teva Dr. Gilgun-Sherki served as a Scientist at Cato Research, where he was responsible for providing scientific and medical insights on clinical studies design, management, and execution of clinical trials, safety monitoring and review & analysis of potential new biotechnologies, and prior to that he served as an investigator and coordinator in clinical trials conducted at the Neurology Department, Rabin Medical Center, and worked with Novia Pharmaceuticals, a biotech company which developed a novel BBB-penetrating product for the treatment of neurodegenerative diseases.
Dr. Gilgun-Sherki holds a PhD from the Sackler Faculty of Medicine, Tel Aviv University, in neuropharmacology, and an MBA from The Open University of Israel. He is a (co)author of over 40 publications and book chapters, and an inventor of 6 patents.